Year of Publication
2024
College
Public Health
Date Available
8-14-2024
Degree Name
Master of Public Health (M.P.H.)
Committee Chair
Dr. Julia Costich
Committee Member
Dr. Chris Delcher
Committee Member
Dr. Jayani Jayawardhana
Abstract
This policy analysis examines the evolving landscape of GLP-1 receptor agonists (GLP-1 RAs) and their implications for Medicare Part D coverage. Initially developed for managing type 2 diabetes, GLP-1 RAs have rapidly gained popularity due to their efficacy in treating obesity and reducing cardiovascular events, leading to broader therapeutic applications. However, access to these medications under Medicare Part D is limited by high costs and coverage restrictions, particularly when used for obesity without diabetes. This analysis evaluates current Medicare Part D policies, including specialty drug tier placement, formulary restrictions, and the potential impact of recent legislative initiatives such as the Inflation Reduction Act and the Treat and Reduce Obesity Act. Through a comprehensive review of clinical trials, policy briefs, and economic assessments, the study identifies significant barriers to patient access and proposes policy reforms to improve the affordability and availability of GLP-1 RAs for Medicare beneficiaries. The findings underscore the need for Medicare to adapt its coverage frameworks to align with the expanding role of GLP-1 RAs in chronic disease management, ensuring equitable access for millions of beneficiaries.
Recommended Citation
Hummer, Celine, "Patient Access to GLP-1 RA’s: A Medicare Part D Policy Analysis" (2024). Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.). 447.
https://uknowledge.uky.edu/cph_etds/447
